Progenics Pharmaceuticals (PGNX) up 1% as Q1 net loss meets Street expectations and revenue falls short.
PGNX reported a net loss of $9.3 million, down from $11.3 million a year prior. Net loss per share was $0.15, down from $0.22 per share a year prior.
Total revenue was $1.8 million, down from $2.2 million a year prior.
The Street expected a loss of $0.15 per share on revenue of $3.4 million, according to Capital IQ estimates.
PGNX trades in a 52-week range of $3.20 to $7.45.
Latest posts by Nathan Fortin (see all)
- The End of Life Option Act Already Used by 111 People - Jun 28, 2017
- Senate Decided to Kill Rule that Promotes Retirement Plans - Apr 1, 2017
- BlackRock Is Turning to Robots for Improved Stocks - Mar 30, 2017